Clinical trials: Alcohol-associated Liver Disease
Alcohol-related Liver Disease, Alcohol Use Disorder
Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden.
Excessive alcohol use is a leading risk factor for preventable disability and death. Alcohol-related liver disease (ALD) is one of the better-known detrimental consequences of alcohol abuse and is the main cause of…
- Conditions
- Alcohol-related Liver Disease, Alcohol Use Disorder, Metabolic and Alcohol Related/Associated Liver Disease, Metabolic Disfunction Associated Steatotic Liver Disease
- Trial name
- StopALD (NCT06403332)
- Testing
- brief intervention
- Where
- 2 sites in Spain
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Alcohol Use Disorder, Alcohol Related Liver Disease
Peer Support for Liver Transplant Recipients With History of ALD
Liver transplant (LT) recipients with a history of alcohol-related liver disease (ALD) may encounter various psychosocial and medical challenges during post-LT recovery, even beyond the initial post-transplant period.
- Conditions
- Alcohol Use Disorder, Alcohol Related Liver Disease, Liver Transplant Recipient
- Trial name
- THRIVE (NCT07397598)
- Testing
- Peer Support
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Johns Hopkins University
Liver Transplant Recipient, Alcohol Use Disorders (AUD)
Intervention for Alcohol Use Disorder Recovery After Liver Transplantation
The goal of this clinical trial is to learn if it is feasible and acceptable to use a recovery coach and an online sober active community to help with alcohol use disorder after liver transplant.
- Trial name
- ILTARP (NCT07214259)
- Testing
- Online Sober Active Community, Recovery coach
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Leigh Anne Dageforde
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
MASLD
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts.
- Trial name
- NCT07024212
- Testing
- DR10624 Injection
- Where
- 4 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Alcohol-associated Fatty Liver Disease
High-Protein Diet for Improving Alcoholic Fatty Liver Disease
Alcohol-associated liver disease (ALD) is a major cause of mortality from malignant liver diseases, accounting for 47.9% of cirrhosis-related deaths and 30% of liver cancer-related deaths annually.
- Trial name
- HP-AFLD-RCT (NCT07632222)
- Testing
- high protein diet, control diet, perilla peptide dietary group
- Volunteers
- 74 people
- Sponsor
- Li Lab,MD
Alcohol Use Disorder, Alcohol-related Liver Disease
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
This protocol describes a randomized controlled trial testing the effectiveness and implementability of the CHESS Health Connections smartphone application among patients with alcohol-associated liver disease (ALD) at two medical…
- Trial name
- IMPACT-ALD (NCT06305624)
- Testing
- Connections App
- Where
- 3 sites in United States
- Volunteers
- 298 people
- Sponsor
- University of Wisconsin, Madison
Alcohol Associated Liver Disease, Heavy Drinking Behavior
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Background: Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver…
- Trial name
- NCT04781322
- Testing
- Alirocumab
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Liver Cirrhosis
A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis
A feasibility trial called PROFIT has previously shown that FMT administered endoscopically into the jejunum in patients with cirrhosis is safe and feasible and have identified some potential mechanisms of action that warrant…
- Trial name
- PROMISE (NCT06461208)
- Testing
- Encapsulated FMT
- Where
- 23 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- King's College London
Metabolic-dysfunction Associated Liver Disease (MASLD)
Testing a Multilevel, Culturally Appropriate Lifestyle Intervention For Hispanic Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
The purpose of this study is to understand if a behavioral lifestyle intervention called the Healthy Liver/Hígado Sano program can help Hispanic/Latino patients with metabolic dysfunction associated steatotic liver disease…
- Trial name
- NCT07199491
- Testing
- Healthy Liver/Hígado Sano program, Usual Care
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center, Houston
Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
The goal of this observational study is to learn if spleen stiffness and other non-invasive markers can help predict recompensation in people with decompensated cirrhosis who are receiving effective treatment for the cause of…
- Conditions
- Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease
- Trial name
- LEAD-2 (NCT07087041)
- Where
- 28 sites in China
- Volunteers
- 735 people
- Sponsor
- Beijing Friendship Hospital
Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease
Investigating Myosteatosis in Steatotic Liver Diseases
Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities …
- Conditions
- Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease of Mixed Origin (MetALD), Steatotic Liver Diseases
- Trial name
- MYO-SLD (NCT06514300)
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Alcohol Use Disorder, Alcohol; Liver
CM for Patients With ALD After Liver Transplant
Alcohol associated liver disease (ALD) refers to liver injury, such as cirrhosis, that is caused by alcohol use. It affects 2 million adults in the U.S.
- Conditions
- Alcohol Use Disorder, Alcohol; Liver, Post Liver Transplant, Contingency Management
- Trial name
- NCT06304467
- Testing
- Contingency Management
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Arpan A. Patel, MD
Alcohol-related Liver Disease
Genetic Polymorphisms Associated With the Risk of Pancreatitis in Patients With Alcohol Related Cirrhosis.
Alcohol is a known risk factor for both pancreatitis and cirrhosis. However, not all patients with alcohol related cirrhosis develop pancreatitis.
- Trial name
- NCT06763198
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Alcoholic Hepatitis
Complex Exploratory Study of Alcohol-Associated Hepatitis
Alcohol-associated hepatitis is a clinical syndrome distinct from steatohepatitis or liver cirrhosis. It is associated with high mortality and characterized by an absence of effective treatment, while corticosteroids, which are…
- Trial name
- CESAH (NCT06358196)
- Where
- Slovakia
- Volunteers
- 100 people
- Sponsor
- Pavol Jozef Safarik University
Alcohol Associated Hepatitis
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
- Trial name
- FRESH (NCT05639543)
- Testing
- INT-787
- Where
- 29 sites in United States, France and 1 more
- Volunteers
- 67 people
- Sponsor
- Intercept Pharmaceuticals
Liver Fibrosis
Screening of Liver Fibrosis in Adults Without Known Liver Disease
SIRIUS is the "serious" response to the prevalence of liver cirrhosis in Slovakia. We plan to screen adult Slovaks without acute or life-threatening comorbidity and without known liver disease (except from non-alcoholic fatty…
- Trial name
- SIRIUS (NCT05486767)
- Testing
- Transient elastography
- Where
- 3 sites in Slovakia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Alcohol Use Disorder, Alcohol-associated Liver Disease
Financial Rewards for Reducing Alcohol Use in Patients With Liver Disease
This study tests whether providing financial rewards based on a blood test result can help people with alcohol-associated liver disease (ALD) stop or reduce their drinking.
- Conditions
- Alcohol Use Disorder, Alcohol-associated Liver Disease, Liver Cirrhosis, Alcoholic, Alcohol-Associated Hepatitis
- Trial name
- REINFORCE (NCT07465588)
- Testing
- PEth Based Contingency Management, PEth Monitoring with Fixed Incentives
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder
Tirzepatide in MetALD
Background: People with alcohol use disorder (AUD) often develop metabolic alcohol-associated liver disease (MetALD). MetALD is a term for the heart, liver, obesity, and other issues that can accompany AUD. MetALD can be fatal.
- Trial name
- NCT07046819
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)